Aripiprazole is the Superior Choice for Augmentation
For a patient on sertraline with persistent passive suicidal ideation, aripiprazole augmentation should be used rather than bupropion (Wellbutrin). This recommendation is based on the most robust evidence demonstrating superior efficacy for aripiprazole in treatment-resistant depression, particularly in the context of suicidal ideation.
Primary Evidence Supporting Aripiprazole
The 2023 OPTIMUM trial 1—the highest quality, most recent head-to-head comparison—directly compared aripiprazole augmentation versus bupropion augmentation in treatment-resistant depression. Aripiprazole augmentation improved psychological well-being significantly more than switching to bupropion (difference of 2.79 points, p=0.014), with a remission rate of 28.9% versus 19.3% for bupropion switch. While this compared aripiprazole augmentation to bupropion switch (not augmentation), the bupropion augmentation group showed similar outcomes to the switch group, suggesting limited benefit from bupropion in either strategy.
Multiple placebo-controlled trials consistently demonstrate aripiprazole's efficacy as augmentation therapy:
- A 2018 Japanese study 2 showed aripiprazole/sertraline combination produced significantly greater MADRS score reduction than placebo/sertraline (-9.2 vs -7.2, p=0.007)
- The 2007 pivotal trial 3 demonstrated mean MADRS improvement of -8.8 with aripiprazole augmentation versus -5.8 with placebo (p<0.001)
- Even low-dose aripiprazole (2.5mg) combined with sertraline showed superior efficacy in fresh major depressive episodes 4
Critical Consideration: Suicidal Ideation
The presence of persistent passive suicidal ideation makes this choice even more critical. Analysis of the STAR*D data 5 revealed that bupropion augmentation was associated with reduced suicidal ideation (OR 0.24, p<0.001) in level two treatment. However, this benefit must be weighed against:
- Overall treatment response: Aripiprazole demonstrates superior antidepressant efficacy, and improvement in suicidal ideation correlates strongly with overall depression improvement across all STAR*D levels
- Treatment resistance context: The STAR*D analysis showed diminishing returns with sequential treatment phases—getting the augmentation choice right initially is paramount
The 2025 VA/DoD guidelines 6 note insufficient evidence for specific pharmacologic interventions targeting suicidal ideation directly, emphasizing the importance of overall depression treatment efficacy.
Practical Implementation
Start aripiprazole at 2-5mg daily as augmentation to the existing sertraline regimen. The 2022 dose-effect meta-analysis 7 demonstrates that low doses (2-5mg) achieve optimal balance between efficacy (OR 1.46-1.93) and tolerability, with no additional benefit from higher doses up to 20mg.
Key Tolerability Considerations
Akathisia is the primary concern with aripiprazole (occurring in 12.9-23.1% of patients 2, 3), but:
- Most cases are mild to moderate
- Discontinuation rates due to adverse events remain low (1.9-2.2%)
- Can be managed with dose reduction or beta-blockers if needed
Important drug interaction: Bupropion inhibits CYP2D6, which metabolizes sertraline 8. Adding bupropion to sertraline may increase sertraline levels, potentially requiring sertraline dose adjustment and complicating management.
Clinical Algorithm
- Add aripiprazole 2mg daily to existing sertraline regimen
- Titrate to 5mg after 1 week if tolerated
- Assess response at 2-4 weeks: Monitor both depressive symptoms and suicidal ideation
- If inadequate response at 4-6 weeks: Consider increasing to 10mg (though evidence suggests limited additional benefit)
- Monitor specifically for akathisia: Use Barnes Akathisia Rating Scale if available
When to Reconsider
If akathisia is intolerable despite management attempts, or if the patient has schizophrenia/schizoaffective disorder with suicidal ideation (where clozapine would be preferred per guidelines 6), alternative strategies should be pursued.
The evidence consistently favors aripiprazole augmentation over bupropion for treatment-resistant depression on sertraline, with the added benefit of avoiding a potentially problematic drug interaction.